By Dr. Mark Rosenberg
If you are considering a GLP-1 medication for weight management or type 2 diabetes, it is reasonable to ask: “They sound similar. Why would my doctor pick one over the other?”
Semaglutide and tirzepatide are both once-weekly injectable medications that can reduce appetite, improve blood sugar, and produce meaningful weight loss. But they are not identical. Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both the GLP-1 receptor and the GIP receptor. That second pathway is the main biological difference and it helps explain why clinical trial results are not exactly the same.
What is GLP-1?
GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut releases after you eat. Its job is to help your body handle incoming nutrients.
GLP-1 does several useful things at once. It tells the pancreas to release insulin when blood sugar is rising. It lowers glucagon, a hormone that tells the liver to release stored glucose. It slows how quickly food leaves the stomach. It also communicates with appetite centers in the brain, helping you feel full sooner and reducing cravings.
That combination is why GLP-1 medicines are used for both type 2 diabetes and weight management. They do not simply “block hunger.” They change the hormonal signals that regulate hunger, satiety, glucose control, and digestion.
What is GIP, and why does tirzepatide hit two receptors?
GIP stands for glucose-dependent insulinotropic polypeptide. Like GLP-1, it is an incretin hormone released by the gut after eating. “Incretin” means it helps the pancreas release insulin in response to food.
For years, GIP was less exciting clinically because people with type 2 diabetes often have impaired GIP responsiveness. Tirzepatide changed the conversation because it activates both GIP and GLP-1 receptors. The exact contribution of GIP is still being studied, but the dual action appears to amplify metabolic effects: stronger glucose-dependent insulin secretion, improved appetite regulation, and possibly effects on fat tissue and energy balance that differ from GLP-1 alone.
That does not mean tirzepatide is “better for everyone.” It means it has a broader receptor profile, and that can matter depending on the patient’s goals, tolerability, insurance coverage, and medical history.
Appetite, stomach emptying, insulin, glucagon, and energy expenditure
Both medications reduce appetite through brain pathways involved in satiety and reward. Patients often describe less “food noise,” smaller portions, and less interest in highly palatable foods.
Both also slow gastric emptying, especially early in treatment. This means food stays in the stomach longer, which can help fullness but can also cause nausea, reflux, bloating, or constipation. The gastric-emptying effect may diminish over time, but GI symptoms often drive the need for slower dose escalation.
For insulin secretion, both drugs are glucose-dependent. That is important. They stimulate insulin more when glucose is elevated and much less when glucose is normal, which is why hypoglycemia risk is generally low unless combined with insulin or sulfonylureas.
Both reduce glucagon, which helps lower hepatic glucose output. Tirzepatide may produce greater HbA1c lowering in many patients, likely because of the combined incretin effect.
Energy expenditure is more complicated. These drugs do not primarily work by “speeding up metabolism.” Weight loss is mostly driven by reduced caloric intake. As body weight drops, resting energy expenditure may decline, which is one reason resistance training and adequate protein are essential, especially for the Bodybuilding.com audience. The goal is not just losing pounds; it is preserving lean mass while reducing fat mass.
What do the clinical trials show?
In obesity trials, semaglutide 2.4 mg produced major weight loss. In the STEP 1 trial, adults with overweight or obesity without diabetes lost an average of 14.9% of body weight at 68 weeks versus 2.4% with placebo.
Tirzepatide also produced substantial weight loss in the SURMOUNT program. In SURMOUNT-1, adults with obesity or overweight without diabetes lost an average of 19.5% with tirzepatide 10 mg and 20.9% with tirzepatide 15 mg at 72 weeks.
There is now head-to-head obesity data. In SURMOUNT-5, tirzepatide was compared directly with semaglutide in adults with obesity or overweight without diabetes. Tirzepatide produced greater reductions in body weight and waist circumference at 72 weeks.
For type 2 diabetes, the key head-to-head trial is SURPASS-2, which compared tirzepatide with semaglutide 1 mg—not the 2.4 mg obesity dose. Tirzepatide was noninferior and superior to semaglutide for HbA1c reduction and also produced greater weight loss over 40 weeks.
Semaglutide also has strong diabetes and cardiometabolic data. In STEP 2, semaglutide 2.4 mg produced clinically meaningful weight loss in people with overweight or obesity and type 2 diabetes. Wegovy also has an FDA-approved cardiovascular risk-reduction indication for adults with established cardiovascular disease and obesity or overweight, based on outcomes data.
Side effects: similar, but not always identical
The most common side effects for both medications are gastrointestinal: nausea, diarrhea, constipation, vomiting, reflux, abdominal discomfort, and reduced appetite. These are usually most noticeable during dose escalation.
Tirzepatide’s FDA labeling lists common adverse reactions including nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection-site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and GERD. Wegovy labeling also emphasizes GI adverse reactions and warns about severe GI reactions, pancreatitis, gallbladder disease, kidney injury from dehydration, and delayed gastric emptying relevant to anesthesia or procedures.
Both are typically dosed once weekly and both require gradual dose escalation. Neither should be viewed as a casual cosmetic shortcut. They are prescription metabolic medications that require monitoring, especially in patients with diabetes, gallbladder disease, pancreatitis history, significant GI disease, kidney vulnerability, eating-disorder history, or those taking insulin or sulfonylureas.
Who might be a better candidate for which?
This should be individualized.
A patient whose top priority is maximum weight reduction and who has no major tolerability or access issues may be offered tirzepatide because the head-to-head obesity data favor greater average weight loss.
A patient with established cardiovascular disease and obesity or overweight may have a strong reason to consider semaglutide because Wegovy has an FDA cardiovascular risk-reduction indication in that population.
A patient with type 2 diabetes who needs aggressive HbA1c lowering may be a good candidate for tirzepatide, particularly given SURPASS-2. But semaglutide remains a powerful diabetes medication with extensive outcomes experience.
A patient who previously did well on one drug, had fewer side effects, or has better insurance coverage for one option may be better served by the medication they can actually take consistently. The “best” drug on paper is not always the best drug for a specific person.
For people who lift, train, or care about body composition, the medication choice is only part of the plan. Protein intake, resistance training, sleep, creatine when appropriate, and adequate micronutrition matter. Rapid weight loss without training can mean unnecessary lean-mass loss.
Cost, availability, and compounded versions
Cost and access can drive real-world decisions. List prices and savings programs change frequently, and insurance coverage can differ dramatically depending on whether the prescription is for type 2 diabetes, obesity, cardiovascular risk reduction, or another indication. Manufacturer savings programs may reduce cash prices for eligible patients, but they are not the same as universal affordability.
Compounded versions are pharmacy-made products intended for situations where an FDA-approved drug cannot meet a specific patient need or when a medication is in shortage. They are not the same as FDA-approved branded products. The FDA has stated that tirzepatide and semaglutide are not currently on the FDA drug shortage list, and FDA policy generally restricts compounding of products that are “essentially copies” of commercially available FDA-approved drugs. In April 2026, the FDA also proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, stating there was no clinical need for outsourcing facilities to compound these from bulk substances.
The bottom line is: semaglutide and tirzepatide are similar, but not interchangeable. Semaglutide is a GLP-1 medication with strong weight, diabetes, and cardiovascular outcomes data. Tirzepatide is a dual GIP/GLP-1 medication with greater average weight loss in head-to-head obesity data and strong glucose-lowering effects. The right choice should come from a clinical conversation.